A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517321-99-00

Acronym

IRd, NMSG#23/15

Enrollment

120

Registered

2024-10-22

Start date

2016-08-01

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloma multiplex

Brief summary

To determine the proportion of patients with undetectable flow MRD with sensitivity of 10-5 at any time during protocol treatment.

Interventions

DRUGRevlimid 10 mg hard capsules

DRUGRevlimid 15 mg hard capsules

DRUGRevlimid 20 mg hard capsules

DRUGIXAZOMIB

DRUGNINLARO 4 mg hard capsules

DRUGRevlimid 25 mg hard capsules

DRUGRevlimid 5 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To determine the proportion of patients with undetectable flow MRD with sensitivity of 10-5 at any time during protocol treatment.	—

Countries

Finland, Lithuania, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026